切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2020, Vol. 14 ›› Issue (04) : 261 -266. doi: 10.3877/cma.j.issn.1674-0785.2020.04.005

所属专题: 文献

临床研究

DNMT3A基因对非M3型急性髓系白血病患者预后的预测价值
任颜1, 许晶1, 任维肖1, 王宏伟,2   
  1. 1. 030001 太原,山西医科大学
    2. 030001 太原,山西医科大学;030001 太原,山西医科大学第二医院血液科
  • 收稿日期:2019-07-05 出版日期:2020-04-15
  • 通信作者: 王宏伟

Prognostic value of DNMT3A gene in patients with non-M3 acute myeloid leukemia

Yan Ren1, Jing Xu1, Weixiao Ren1, Hongwei Wang,2   

  1. 1. Shanxi Medical University, Taiyuan 030001, China
    2. Shanxi Medical University, Taiyuan 030001, China; Department of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China
  • Received:2019-07-05 Published:2020-04-15
  • Corresponding author: Hongwei Wang
  • About author:
    Corresponding author: Wang Hongwei, Email:
引用本文:

任颜, 许晶, 任维肖, 王宏伟. DNMT3A基因对非M3型急性髓系白血病患者预后的预测价值[J/OL]. 中华临床医师杂志(电子版), 2020, 14(04): 261-266.

Yan Ren, Jing Xu, Weixiao Ren, Hongwei Wang. Prognostic value of DNMT3A gene in patients with non-M3 acute myeloid leukemia[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2020, 14(04): 261-266.

目的

通过分析非M3型急性髓系白血病(AML)患者的临床和实验室资料,进一步阐明DNMT3A基因突变在非M3型AML患者预后中的意义及其影响AML发生发展的可能机制。

方法

采用R语言3.5.1版本RTCGAToolbox包下载癌症基因组图谱数据库180例非M3型AML患者临床及突变信息,数据为开放性数据。将患者按照突变状态进行分组,比较各组患者外周血白细胞计数、骨髓原始细胞比例、无事件生存期以及总体生存期有无差别。将患者按照年龄分为<60岁组和≥60岁组,使用Kaplan-Meier方法绘制生存曲线,并运用Log-rank检验进行<60岁和≥60岁患者、DNMT3A突变组及野生组患者生存率的比较。采用Cox比例风险模型进行DNMT3A突变和其伴随突变及年龄分层等因素对患者总体生存期的单因素和多因素分析。

结果

共纳入非M3型AML患者180例,DNMT3A突变组与野生组患者临床特征比较发现突变组白细胞计数显著高于野生组(Z=-2.606,P=0.009),且DNMT3A突变多见于中危患者。值得注意的是,DNMT3A突变常伴随FLT3(P=0.025)、NPM1(P<0.001)、IDH1(P=0.002)突变的发生,且DNMT3Awt/FLT3wt组无事件生存期显著高于DNMT3Amut/FLT3mut组(11.00个月vs 6.15个月,P=0.005),而与DNMT3Amut/FLT3wt、DNMT3Awt/FLT3mut组之间的差异无统计学意义。Cox多因素分析结果显示,高龄是AML患者总体生存的独立危险因素(HR=2.974,95%CI:1.966~4.500,P<0.001);另外,DNMT3A R882突变是AML患者预后不良的独立预测因子(HR=1.937,95%CI:1.179~3.182,P=0.009)。

结论

高龄(≥60岁)和DNMT3A R882突变为预后不良的独立预测因子。DNMT3Amut/FLT3mut亚型与DNMT3Awt/FLT3wt、DNMT3Amut/FLT3wt、DNMT3Awt/FLT3mut相比,临床预后更差。

Objective

To further clarify the significance of DNMT3A gene mutations in the prognosis of acute myeloid leukemia (AML) patients and the possible mechanism for its impact on the development of AML by analyzing the clinical and laboratory data of non-M3 AML patients.

Methods

R language software was used to download the clinical and mutation data of non-M3 AML patients from The Cancer Genome Atlas (TCGA). The patients were divided into groups according to the mutation status, and the differences of peripheral blood leukocyte count (WBC), proportion of bone marrow primordial cells, event free survival, and overall survival (OS) were compared. The patients were also divided into groups according to their age and survival curves were plotted using the Kaplan-Meier method. The log-rank test was used to compare the survival rate between patients younger than 60 years old and those older than 60 years old, as well as between the DNMT3A mutation group and the wild type group. Cox proportional risk model was used to conduct single- and multiple-factor analyses of the impact of factors such as DNMT3A mutation, its accompanying mutation, and age stratification on the OS of patients.

Results

A total of 180 non-M3 AML patients were included. WBC in the mutation group was significantly higher than that in the wild type group (Z=-2.606, P=0.009), and the mutation of DNMT3A was more common in the middle risk patients. Mutations of DNMT3A often occurred together with FLT3, NPM1, and IDH1 mutations. The event-free survival of the DNMT3Awt/FLT3wt group was significantly longer than that of the DNMT3Amut/FLT3mut group (11.00 months vs 6.15 months, P=0.005), but had no significant difference compared with that of the DNMT3Amut/FLT3wt or DNMT3Awt/FLT3mut group. Cox multivariate analysis showed that advanced age was an independent risk factor for OS of AML patients (P<0.001). DNMT3A R882 mutation was an independent predictor of poor prognosis in AML patients (P=0.009).

Conclusion

Age over 60 years and DNMT3AR882 mutation are independent predictors of poor prognosis. Compared with patients with DNMT3Awt/FLT3wt, DNMT3Amut/FLT3wt, and DNMT3Awt/FLT3mut, patients with DNMT3Amut/FLT3mut have worse clinical consequences.

表1 180例非M3型急性髓系白血病患者的临床基本特征分析
表2 DNMT3A突变组与野生组患者临床特征的比较
表3 非M3型急性髓系白血病患者总生存的单因素分析
表4 非M3型急性髓系白血病患者总生存的多因素分析
1
Shlush LI, Mitchell A. AML evolution from preleukemia to leukemia and relapse[J]. Best Pract Res Clin Haematol, 2015, 28(2-3): 81-89.
2
Stoll D, Akbani R. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia[J]. N Engl J Med, 2013, 368(22): 2059-2074.
3
Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia[J]. N Engl J Med, 2016, 374(23): 2209-2221.
4
Jennifer S, Ramiro G. Acute Myeloid Leukemia: A Concise Review[J]. J Clin Med, 2016, 5(3): 33.
5
Bose P, Vachhani P, Cortes JE. Treatment of Relapsed/Refractory Acute Myeloid Leukemia[J]. Curr Treat Options Oncol, 2017, 18(3): 17.
6
Saygin C, Carraway HE. Emerging therapies for acute myeloid leukemia[J]. J Hematol Oncol, 2017, 10(1): 93.
7
Chaudry SF, Chevassut TJT. Epigenetic Guardian: A Review of the DNA Methyltransferase DNMT3A in Acute Myeloid Leukaemia and Clonal Haematopoiesis[J]. Biomed Res Int, 2017, 2017: 1-13.
8
Robertson KD, Uzvolgyi E, Liang G, et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors[J]. Nucleic Acids Res, 1999, 27(11): 2291-2298.
9
Chen B, Wang YY, Shen Y, et al. Newly diagnosed acute lymphoblastic leukemia in China (I): abnormal genetic patterns in 1346 childhood and adult cases and their comparison with the reports from Western countries[J]. Leukemia (08876924), 2012, 26(7): 1608.
10
Mi JQ, Wang X, Yao Y, et al. Newly diagnosed acute lymphoblastic leukemia in China (II): prognosis related to genetic abnormalities in a series of 1091 cases[J]. Leukemia, 2012, 26(7): 1507-1516.
11
Kawamata N, Moreilhon C, Saitoh T, et al. Genetic differences between Asian and Caucasian chronic lymphocytic leukemia[J]. Int J Oncol, 2013, 43(2): 561-565.
12
Wang S, Zhang YX, Huang T, et al. Mutation profile and associated clinical features in Chinese patients with cytogenetically normal acute myeloid leukemia[J]. Int J Lab Hematol, 2018, 40(4): 408-418.
13
Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel[J]. Blood, 2017, 129(4): 424-447.
14
中华医学会血液学分会白血病淋巴瘤学组. 成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2017年版)[J]. 中华血液学杂志, 2017, 38(3): 177-182.
15
Emperle M, Rajavelu A, Kunert S, et al. The DNMT3A R882H mutant displays altered flanking sequence preferences[J]. Nucleic Acids Res, 2018, 46(6): 3130-3139.
16
Loghavi S, Zuo Z, Ravandi F, et al.Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations[J]. J Hematol Oncol, 2014, 7(1): 74.
17
Kumar D, Mehta A, Panigrahi MK, et al. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations[J]. Hematol Oncol Stem Cell Ther, 2018, 11(2): 82-89.
18
Ahmad F, Mohota R, Sanap S, et al. Molecular Evaluation of DNMT3A and IDH1/2 Gene Mutation: Frequency, Distribution Pattern and Associations with Additional Molecular Markers in Normal Karyotype Indian Acute Myeloid Leukemia Patients[J]. Asian Pac J Cancer Prev, 2014, 15(3): 1247-1253.
19
Straube J, Ling VY, Hill GR, et al. The impact of age, NPM1 mut and FLT3-ITD allelic ratio in patients with acute myeloid leukemia[J]. Blood, 2018, 131(10): 1148-1153.
20
Zhang X, Zhao Z, Yi S, et al. Deguelin induced differentiation of mutated NPM1 acute myeloid leukemia in vivo and in vitro[J]. Anticancer Drugs, 2017, 28(7): 723-738.
21
Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 Mutations Result in?a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation[J]. Cancer Cell, 2010, 18(6): 553-567.
22
Meyer SE, Qin T, Muench DE, et al. DNMT3A Haploinsufficiency Transforms FLT3-ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia[J]. Cancer Discov, 2016, 6(5): 501-515.
[1] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[2] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[3] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[4] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[5] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[6] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[7] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[8] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[9] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[10] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[11] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[12] 曾明芬, 王艳. 急性胰腺炎合并脂肪肝患者CT 与彩色多普勒超声诊断参数与其病情和预后的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 531-535.
[13] 沈炎, 张俊峰, 唐春芳. 预后营养指数结合血清降钙素原、胱抑素C及视黄醇结合蛋白对急性胰腺炎并发急性肾损伤的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 536-540.
[14] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文
3
HTML PDF
最新录用 在线预览 正式出版 最新录用 在线预览 正式出版
0 0 2 0 0 1

  来源 本网站 其他网站
  次数 2 1
  比例 67% 33%

摘要
135
最新录用 在线预览 正式出版
0 0 135
  来源 本网站 其他网站
  次数 60 75
  比例 44% 56%